Elicio Therapeutics (NASDAQ: ELTX) net income
Elicio Therapeutics reported a net loss of $39.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $51.9m. Earnings per share were −$2.58.
Elicio Therapeutics's best year of the last 6 was fiscal 2022. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$39.6m | — | — | −$2.58 |
| 2024 | −$51.9m | — | — | −$4.25 |
| 2023 | −$35.2m | — | — | −$6.96 |
| 2022 | −$28.2m | — | −1,225.9% | −$89.27 |
| 2021 | −$54.6m | — | −192.8% | −$1.93 |
| 2020 | −$80.1m | — | −2,781.5% | −$5.43 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Elicio Therapeutics net income compared with its sector
By net income for its latest fiscal year, Elicio Therapeutics ranks 241st of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 239th | Spruce Biosciences | −$39.0m | — |
| 240th | TriSalus Life Sciences | −$39.2m | −86.9% |
| 241st | Elicio Therapeutics | −$39.6m | — |
| 242nd | OrthoPediatrics | −$39.6m | −16.8% |
| 243rd | Palvella Therapeutics | −$41.7m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Elicio Therapeutics
- How much did Elicio Therapeutics earn in fiscal 2025?
- Elicio Therapeutics reported a net loss of $39.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $51.9m.
- What are the earnings per share of Elicio Therapeutics?
- They were −$2.58 in fiscal 2025, compared with −$4.25 in fiscal 2024.
- Where does Elicio Therapeutics rank in its sector by net income?
- It ranks 241st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Elicio Therapeutics come from?
- From the annual report (Form 10-K) that Elicio Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Elicio Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Elicio Therapeutics: the Elicio Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.